{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:51:47Z","timestamp":1793681507449,"version":"4.5.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01241-9","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T16:06:32Z","timestamp":1745510792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study"],"prefix":"10.1038","volume":"15","author":[{"given":"Cl\u00e9mentine","family":"Sarkozy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-3501","authenticated-orcid":false,"given":"Remy","family":"Gressin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-2448","authenticated-orcid":false,"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-5419","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Safar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"Beno\u00eet","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-3882","authenticated-orcid":false,"given":"Ghandi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-8983","authenticated-orcid":false,"given":"Ren\u00e9 Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9260-8340","authenticated-orcid":false,"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Delfau-Larue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0520-0493","authenticated-orcid":false,"given":"Elizabeth","family":"Macintyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Callanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-1389","authenticated-orcid":false,"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-9581","authenticated-orcid":false,"given":"Morgane","family":"Cheminant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"1241_CR1","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantle-cell lymphoma. New Engl J Med. 2012;367:520\u201331.","journal-title":"New Engl J Med."},{"key":"1241_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1200\/JCO.19.01294","volume":"38","author":"HC Kluin-Nelemans","year":"2020","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial. J Clin Oncol. 2020;38:248\u201356.","journal-title":"J Clin Oncol."},{"key":"1241_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1200\/JCO.22.01780","volume":"41","author":"O Hermine","year":"2023","unstructured":"Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, et al. High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European mantle cell lymphoma network. J Clin Oncol. 2023;41:479\u201384.","journal-title":"J Clin Oncol."},{"key":"1241_CR4","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","volume":"5","author":"CW Eskelund","year":"2020","unstructured":"Eskelund CW, Dimopoulos K, Kolstad A, Glimelius I, R\u00e4ty R, Gjerdrum L, et al. Detailed long-term follow-up of patients who relapsed after the Nordic mantle cell lymphoma trials: MCL2 and MCL3. HemaSphere. 2020;5:e510.","journal-title":"HemaSphere"},{"key":"1241_CR5","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Damaj G, et al. Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA trial: a LYSA study. J Clin Oncol. 2023;42:769\u201373.","DOI":"10.1200\/JCO.23.01586"},{"key":"1241_CR6","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. New Engl J Med. 2017;377:1250\u201360.","journal-title":"New Engl J Med."},{"key":"1241_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565\u201375.","journal-title":"Lancet"},{"key":"1241_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","volume":"121","author":"R Delarue","year":"2013","unstructured":"Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Blood. 2013;121:48\u201353.","journal-title":"Blood"},{"key":"1241_CR9","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","volume":"123","author":"A Kolstad","year":"2014","unstructured":"Kolstad A, Laurell A, Jerkeman M, Gr\u00f8nb\u00e6k K, Elonen E, R\u00e4ty R, et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma. Blood. 2014;123:2953\u20139.","journal-title":"Blood"},{"key":"1241_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/blood.2023020984","volume":"143","author":"C Bommier","year":"2024","unstructured":"Bommier C, Zucca E, Chevret S, Conconi A, Nowakowski G, Maurer MJ, et al. Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy. Blood. 2024;143:422\u20138.","journal-title":"Blood"},{"key":"1241_CR11","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139:1684\u201393.","journal-title":"Blood"},{"key":"1241_CR12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood.2019001088","volume":"134","author":"S Luminari","year":"2019","unstructured":"Luminari S, Merli M, Rattotti S, Tarantino V, Marcheselli L, Cavallo F, et al. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood. 2019;134:798\u2013801.","journal-title":"Blood"},{"key":"1241_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-023-01448-y","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla N, Welkie RL, Torka P, Shouse G, Karmali R, Shea L, et al. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: a US multisite study. J Hematol Oncol J Hematol Oncol 2023;16:49.","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"1241_CR14","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","volume":"25","author":"S Dietrich","year":"2014","unstructured":"Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J, et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol J Eur Soc Med Oncol. 2014;25:1053\u20138.","journal-title":"Ann Oncol J Eur Soc Med Oncol."},{"key":"1241_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/bjh.15643","volume":"185","author":"C Visco","year":"2019","unstructured":"Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185:940\u20134.","journal-title":"Br J Haematol."},{"key":"1241_CR16","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1182\/bloodadvances.2021004765","volume":"5","author":"DA Bond","year":"2021","unstructured":"Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021;5:5179\u201389.","journal-title":"Blood Adv"},{"key":"1241_CR17","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","volume":"32","author":"E Hoster","year":"2014","unstructured":"Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol J Am Soc Clin Oncol 2014;32:1338\u201346.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"1241_CR18","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","volume":"34","author":"E Hoster","year":"2016","unstructured":"Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J Clin Oncol. 2016;34:1386\u201394.","journal-title":"J Clin Oncol."},{"key":"1241_CR19","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","volume":"37","author":"G Scheubeck","year":"2023","unstructured":"Scheubeck G, Jiang L, Hermine O, Kluin-Nelemans HC, Schmidt C, Unterhalt M, et al. Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia. 2023;37:1887\u201394.","journal-title":"Leukemia"},{"key":"1241_CR20","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1016\/S2352-3026(20)30291-X","volume":"7","author":"S Le Gouill","year":"2020","unstructured":"Le Gouill S, Beldi-Ferchiou A, Alcantara M, Cacheux V, Safar V, Burroni B, et al. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet Haematol. 2020;7:e798\u2013e807.","journal-title":"Lancet Haematol"},{"key":"1241_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3324\/haematol.2018.191429","volume":"104","author":"R Gressin","year":"2019","unstructured":"Gressin R, Daguindau N, Tempescul A, Moreau A, Carras S, Tchernonog E, et al. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Haematologica. 2019;104:138\u201346.","journal-title":"Haematologica"},{"key":"1241_CR22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1182\/blood-2023-188788","volume":"142","author":"V Ribrag","year":"2023","unstructured":"Ribrag V, Safar V, Kluin-Nelemans H, Oberic L, Feugier P, Casasnovas O, et al. Induction and maintenance therapy in elderly patients with mantle cell lymphoma: double-randomized MCL R2 elderly clinical trial by the European Mantle Cell Lymphoma Network. Blood. 2023;142:979.","journal-title":"Blood"},{"key":"1241_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/hon.3164_346","volume":"41","author":"S Ekberg","year":"2023","unstructured":"Ekberg S, Glimelius I, Albertsson-Lindblad A, Weibull CE. Timing of disease progression and impact on survival in Swedish mantle cell lymphoma patients\u2014a novel illness-death model study. Hematol Oncol. 2023;41:471\u20132.","journal-title":"Hematol Oncol."},{"key":"1241_CR24","doi-asserted-by":"crossref","unstructured":"Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, et al. Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts. J. Clin. Oncol. 2022;41:541\u201354.","DOI":"10.1200\/JCO.21.02698"},{"key":"1241_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3324\/haematol.2021.279037","volume":"107","author":"A Albertsson-Lindblad","year":"2022","unstructured":"Albertsson-Lindblad A, Palsdottir T, Smedby KE, Weibull C, Glimelius I, Jerkeman M. Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen\u2014a real world study on patients diagnosed in Sweden 2007-2017. Haematologica. 2022;107:740\u20133.","journal-title":"Haematologica"},{"key":"1241_CR26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1182\/blood.2023023525","volume":"144","author":"C Malinverni","year":"2024","unstructured":"Malinverni C, Bernardelli A, Glimelius I, Mirandola M, Smedby KE, Tisi MC, et al. Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study. Blood. 2024;144:1001\u20139. 2023023525","journal-title":"Blood"},{"key":"1241_CR27","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903\u201310.","journal-title":"Blood"},{"key":"1241_CR28","first-page":"1857","volume":"109","author":"S Carras","year":"2024","unstructured":"Carras S, Torroja A, Emadali A, Montaut E, Daguindau N, Tempescul A, et al. Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group. Haematologica. 2024;109:1857\u201365.","journal-title":"Haematologica"},{"key":"1241_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","volume":"131","author":"SM Aukema","year":"2018","unstructured":"Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018;131:417\u201320.","journal-title":"Blood"},{"key":"1241_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","volume":"126","author":"M-H Delfau-Larue","year":"2015","unstructured":"Delfau-Larue M-H, Klapper W, Berger F, Jardin F, Briere J, Salles G, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126:604\u201311.","journal-title":"Blood"},{"key":"1241_CR31","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","volume":"105","author":"S Ferrero","year":"2020","unstructured":"Ferrero S, Rossi D, Rinaldi A, Bruscaggin A, Spina V, Eskelund CW, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105:1604\u201312.","journal-title":"Haematologica"},{"key":"1241_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood.2020005289","volume":"136","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Martin-Garcia D, Clot G, D\u00edaz-Navarro A, Duran-Ferrer M, Navarro A, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020;136:1419\u201332.","journal-title":"Blood"},{"key":"1241_CR33","doi-asserted-by":"crossref","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E, Jerkeman M, Walewski J, Hutchings M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293\u201306.","DOI":"10.1016\/S0140-6736(24)00184-3"},{"key":"1241_CR34","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. New Engl J Med. 2022;386:2482\u201394.","journal-title":"New Engl J Med."},{"key":"1241_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1182\/blood-2024-199710","volume":"144","author":"DJ Lewis","year":"2024","unstructured":"Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Pasanen A, et al. Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: results from the International Randomised Controlled Trial, Enrich. Blood. 2024;144:235.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01241-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01241-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01241-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T16:06:36Z","timestamp":1745510796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01241-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01241-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MC reports honoraria from Amgen, CSL Behring, Astra Zeneca, Lilly, and Abbvie; research funding from Innate Pharma, Force Hemato, and Servier; travel and accommodation expenses from Pfizer, Griffols, CSL Behring, Astra Zeneca, Lilly, and Gilead but no competing financial interests for this study. FM reports consultancy for Roche\/Genentech; and advisory boards for Roche, BMS, Gilead, Novartis, Epizyme, Genmab, AbbVie, and Kymera. VS reports consultancy for Kite\/Gilead, Janssen; fundings from Janssen, Abbvie. The remaining authors declare no competing financial interests for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from all participants, who were included in the previously published clinical trial (EU-MCL younger [] NCT00209222, LyMA [] NCT00921414, LyMA101 [] NCT02896582, EU-MCL elderly [] NCT00209209, RiBVD [] NCT01457144 and MCL-R2 [] NCT01865110). The studies were approved by an independent ethics committee and conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"78"}}